Mala Maini

Has grant

Professor of Viral Immunology

UCL

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Mala Maini is a Professor of Viral Immunology at UCL in the UK. Her research focuses on viral immunology, particularly in relation to chronic HBV and HIV/HBV coinfection, as well as immune responses to SARS-CoV-2. Recent publications highlight her work on liver immune regulation, T cell activity in chronic infections, and the effects of vaccination on respiratory mucosal immunity.

Recent Grants

Grant: Close

ISOPLEXIS platform for single cell multiplexed functional proteomics of immune cells

Open Date: 2021-09-20

Close Date: 2024-09-19

Grant: Close

A UK underpinning platform to study immunology and immunopathology of COVID-19:The UK Coronavirus Immunology Consortium

Open Date: 2020-08-19

Close Date: 2021-08-18

Grant: Close

THERVACB: A THERAPEUTIC VACCINE TO CURE HEPATITIS B

Open Date: 2020-01-01

Close Date: 2024-12-31

Grant: Close

The impact of B cell phenotypes in HIV infection on antibody responses.

Open Date: 2019-09-22

Close Date: 2023-09-29

Grant: Close

Harnessing tissue-resident CD8 T cells to manipulate hepatic immunity

Open Date: 2019-09-01

Close Date: 2024-08-31

Articles (19)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (15)

Elena Mitsi

University of Oxford

UNITED KINGDOM

Mala Maini

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (19)

HIV/HBV co-infection remodels the immune landscape and Natural Killer cell ADCC functional responses.

A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection

Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes.

Persistent symptoms after COVID-19 are not associated with differential SARS-CoV-2 antibody or T cell immunity

The scientific basis of combination therapy for chronic hepatitis B functional cure

Large clones of pre-existing T cells drive early immunity against SARS-COV-2 and LCMV infection

Human resident liver myeloid cells protect against metabolic stress in obesity

Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination.

Tissue T cells in prophylactic and therapeutic vaccination responses

T cell control of SARS-CoV-2: When, which, and where?

An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity.

Airway-resident T cells from unexposed individuals cross-recognize SARS-CoV-2

Liver-resident memory T cells: life in lockdown

Immunotherapies for hepatocellular carcinoma

Human antiviral B cell responses: Emerging lessons from hepatitis B and COVID‐19

Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection

Therapeutic potential of TLR8 agonist GS-9688 (selgantolimod) in chronic hepatitis B: re-modelling of antiviral and regulatory mediators.

Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.

Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection.

Collaborators (15)

Elena Mitsi

Jitao David Zhang

Aine McKnight

Seng Gee Lim

Daniel Altmann

Julian Knight

Ewa Ellis

David Goldblatt

Andreas Tiffeau-Mayer

Kelly Andreia Sullivan da Costa

George Joy

Stephan P. Rosshart

Simon Draper

Daniela M Ferreira

Thomas F. Baumert

Make your next move.